Albany, New York, 29 April 2015 : A new report on the liver cancer therapies
market is now available on Market Research Reports Search Engine (MRRSE), the
portal has announced. The report, titled ‘Frontier Pharma: Liver Cancer -
Identifying and Commercializing First-in-Class Innovation’, by Market Research Report Search Engine (MRRSE), engages in a detailed
analysis of the market and its therapies landscape. The report opens with a
succinct prologue on liver cancer, its symptoms, pathophysiology, and treatment
algorithms before delving on how the molecular landscape of the market is
undergoing a change.
It also pinpoints areas where
maximum innovation is concentrated and offers insight into first-in-class
therapies on the anvil (based on their development stage). Since patent and
licensing trends are an inextricable aspect of the liver cancer market, these are
discussed in detail as well.
According to analysts who have
composed the report, the current liver cancer pipeline features about 238
products at the active stage of development. Of these, 47% are observed to be
in the first-in-class therapies category. A sizeable portion of the pipeline is
focused solely on innovative products – this figure is higher than the average
recorded in the overall pharmaceutical industry and oncology.
According to the report, the
greatest trend in the liver cancer market currently is the calibration of
first-in-class molecular targets with causes of liver cancer. As the industry
increasingly aligns with a heightened understanding of abnormalities in signaling
pathways and the reason for liver cancer, the change is visible in the
pipeline.
Furthermore, the report states
that a number of active deals in the liver cancer market have been reported in
recent years. For a more inclusive study of the agreements and partnerships
reported in the liver cancer market over the past few years, the report studies
major licensing and co-development deals between 2006 and 2014.
A closer look at the market
reveals that a vast contrast exists between the larger market and the lineup of
therapies. Currently, the liver cancer market is composed of 70 products of
which most are generic chemotherapy formulations that are not normally used.
The report identifies Nexavar (sorafenib) as the current dominant therapeutic
in the liver cancer market. On the other hand, an analysis of the pipeline
reveals that a greater emphasis is laid on targeted therapies in the pipeline
than in the current market. These facets of the market stand testimony to the
fact that innovation and diversity are the tools that will help improve the
status of the liver cancer market.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
1.1 List of Tables
1.2 List of Figures
Send An
Enquiry : http://www.mrrse.com/enquiry/110
2 Executive Summary
2.1 Unmet Needs and Limited Market Drive an Innovative Pipeline
2.2 Targeted Therapies Segment to Expand over the Coming Decade
2.3 Active Deals Landscape Reflects the Dynamic Pipeline
2.1 Unmet Needs and Limited Market Drive an Innovative Pipeline
2.2 Targeted Therapies Segment to Expand over the Coming Decade
2.3 Active Deals Landscape Reflects the Dynamic Pipeline
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 GBI Research Report Guidance
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 GBI Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Symptoms
4.3 Epidemiology and Etiology
4.4 Pathophysiology
4.4.1 Hepatocellular Carcinoma
4.4.2 Cholangiocarcinoma
4.4.3 Conclusion
4.5 Diagnosis
4.5.1 Clinical Presentation
4.5.2 Alpha-Fetoprotein
4.5.3 Diagnostic Imaging and Scans
4.5.4 Screening
4.5.5 Biopsy
4.5.6 Classification
4.6 Treatment Options
4.7 Treatment Algorithm
4.7.1 First Line
4.8 Overview of Marketed Products for Liver Cancer
4.8.1 Molecular Type and Target Analysis
4.8.2 Innovative Products in the Liver Cancer Market
4.8.3 Unmet Needs
4.1 Disease Overview
4.2 Symptoms
4.3 Epidemiology and Etiology
4.4 Pathophysiology
4.4.1 Hepatocellular Carcinoma
4.4.2 Cholangiocarcinoma
4.4.3 Conclusion
4.5 Diagnosis
4.5.1 Clinical Presentation
4.5.2 Alpha-Fetoprotein
4.5.3 Diagnostic Imaging and Scans
4.5.4 Screening
4.5.5 Biopsy
4.5.6 Classification
4.6 Treatment Options
4.7 Treatment Algorithm
4.7.1 First Line
4.8 Overview of Marketed Products for Liver Cancer
4.8.1 Molecular Type and Target Analysis
4.8.2 Innovative Products in the Liver Cancer Market
4.8.3 Unmet Needs
5 Assessment of Pipeline Product Innovation
5.1 Liver Cancer Pipeline by Molecule Type, Phase and Therapeutic Target
5.2 Comparative Distribution of Programs between the Liver Cancer Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets
5.1 Liver Cancer Pipeline by Molecule Type, Phase and Therapeutic Target
5.2 Comparative Distribution of Programs between the Liver Cancer Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets
6 Liver Cancer Patent Family Analysis
7 Signaling Network, Disease Causation and Innovation Alignment
7.1 The Complexity of Signaling Networks in Oncology
7.2 Signaling Pathways Disease-Causing Mutations and First-in-Class Molecular Target Integration
7.3 First-in-Class Target Matrix Assessment
7.1 The Complexity of Signaling Networks in Oncology
7.2 Signaling Pathways Disease-Causing Mutations and First-in-Class Molecular Target Integration
7.3 First-in-Class Target Matrix Assessment
8 First-in-Class Target Evaluation
8.1 Pipeline Programs Targeting ß-Catenin
8.2 Pipeline Programs Targeting FGFR4
8.3 Pipeline Programs Targeting GPR55
8.4 Pipeline Programs Targeting Protein Disulfide Isomerase
8.5 Pipeline Programs Targeting Telomerase
8.6 Pipeline Programs Targeting Delta-Like 1 Homolog
8.7 Pipeline Programs Targeting eIF5A
8.8 Pipeline Programs Targeting FAK
8.9 Pipeline Programs Targeting TGFß Receptor
8.10 Conclusion
8.1 Pipeline Programs Targeting ß-Catenin
8.2 Pipeline Programs Targeting FGFR4
8.3 Pipeline Programs Targeting GPR55
8.4 Pipeline Programs Targeting Protein Disulfide Isomerase
8.5 Pipeline Programs Targeting Telomerase
8.6 Pipeline Programs Targeting Delta-Like 1 Homolog
8.7 Pipeline Programs Targeting eIF5A
8.8 Pipeline Programs Targeting FAK
8.9 Pipeline Programs Targeting TGFß Receptor
8.10 Conclusion
9 Deals and Strategic Consolidations
9.1 Industry-wide First-in-Class Deals
9.2 Liver Cancer Deals Landscape
9.3 Licensing Deals
9.3.1 Molecule Types
9.3.2 Mechanism of Action
9.4 Co-Development Deals
9.4.1 Molecule Types
9.4.2 Mechanism of Action
9.5 First-In-Class Programs Not Involved in Licensing or Co-Development Deals
9.1 Industry-wide First-in-Class Deals
9.2 Liver Cancer Deals Landscape
9.3 Licensing Deals
9.3.1 Molecule Types
9.3.2 Mechanism of Action
9.4 Co-Development Deals
9.4.1 Molecule Types
9.4.2 Mechanism of Action
9.5 First-In-Class Programs Not Involved in Licensing or Co-Development Deals
10 Appendix
10.1 References
10.2 Abbreviations
10.3 Contact Us
10.4 Disclaimer
10.1 References
10.2 Abbreviations
10.3 Contact Us
10.4 Disclaimer
About Us
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other
keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
Us:
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
Email:
sales@mrrse.com
Website:
http://www.mrrse.com/
Blog: http://mrrse.blogspot.com/